Press Release

Calidi Biotherapeutics, Inc. Granted New Patent from USPTO for Cell-Based Delivery Of Oncolytic Vaccinia Viruses

SAN DIEGO, October 25, 2018 - Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced that it has been granted a new patent from the United States Patent Office (USPTO). Patent Number: 10,105,436 "Smallpox Vaccine for Cancer Treatment" covers the use…
Calidi Biotherapeutics
October 25, 2018